日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

MetaMind: A multi-agent transformer-driven framework for automated network meta-analyses

MetaMind：一个用于自动化网络元分析的多智能体Transformer驱动框架

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0342895
Livieratos, Achilleas; Kudela, Maria; Zhao, Yuxi; Chen, All-Shine; Luo, Xin; Lin, Junjing; Zhang, Di; Dharmarajan, Sai; Tsiodras, Sotirios; Rudrapatna, Vivek; Gamalo, Margaret
发表日期：2026
文献求助 收藏

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

更正：托法替尼在银屑病关节炎和类风湿性关节炎患者中9年上市后安全性监测

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-023-00615-4
Burmester, Gerd R; Coates, Laura C; Cohen, Stanley B; Tanaka, Yoshiya; Vranic, Ivana; Nagy, Edward; Lazariciu, Irina; Chen, All-Shine; Kwok, Kenneth; Fallon, Lara; Kinch, Cassandra
关节炎
银屑病
发表日期：2024
文献求助 收藏

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

托法替尼在银屑病关节炎和类风湿性关节炎患者中9年上市后安全性监测

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-023-00576-8
Burmester, Gerd R; Coates, Laura C; Cohen, Stanley B; Tanaka, Yoshiya; Vranic, Ivana; Nagy, Edward; Lazariciu, Irina; Chen, All-Shine; Kwok, Kenneth; Fallon, Lara; Kinch, Cassandra
关节炎
银屑病
发表日期：2023
文献求助 收藏

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial

接受托法替尼治疗与接受肿瘤坏死因子抑制剂治疗的类风湿性关节炎患者的感染情况：来自开放标签、随机对照的 ORAL 监测试验的结果

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard-2022-222405
Balanescu, Andra-Rodica; Citera, Gustavo; Pascual-Ramos, Virginia; Bhatt, Deepak L; Connell, Carol A; Gold, David; Chen, All-Shine; Sawyerr, Gosford; Shapiro, Andrea B; Pope, Janet E; Schulze-Koops, Hendrik
炎症/感染
关节炎
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏